Opexa Therapeutics Announces Closing of Partial Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
Published: Sep 04, 2013
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 650,000 shares of its common stock, at a price to the public of $1.50 per share, in connection with the Company’s recently announced underwritten public offering of 12,000,000 shares of common stock, bringing total gross proceeds from the offering to $18,975,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Help employers find you! Check out all the jobs and post your resume.